Concepts (293)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mitochondria | 29 | 2025 | 523 | 4.650 |
Why?
|
| HIV Infections | 48 | 2026 | 2586 | 3.400 |
Why?
|
| Anti-HIV Agents | 16 | 2026 | 486 | 3.000 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 11 | 2019 | 31 | 2.810 |
Why?
|
| DNA, Mitochondrial | 22 | 2025 | 191 | 2.740 |
Why?
|
| Adipose Tissue | 10 | 2025 | 182 | 2.620 |
Why?
|
| Insulin Resistance | 10 | 2025 | 201 | 2.400 |
Why?
|
| Leukocytes, Mononuclear | 17 | 2025 | 247 | 2.200 |
Why?
|
| Pregnancy Complications, Infectious | 5 | 2025 | 117 | 1.440 |
Why?
|
| Reverse Transcriptase Inhibitors | 7 | 2019 | 57 | 1.210 |
Why?
|
| Genes, Mitochondrial | 1 | 2025 | 14 | 0.930 |
Why?
|
| Inflammation | 7 | 2026 | 758 | 0.810 |
Why?
|
| Adenine | 5 | 2012 | 46 | 0.790 |
Why?
|
| Transcription, Genetic | 1 | 2025 | 592 | 0.750 |
Why?
|
| Lamivudine | 7 | 2025 | 22 | 0.720 |
Why?
|
| Adipocytes | 2 | 2019 | 60 | 0.680 |
Why?
|
| Adenosine Triphosphate | 3 | 2024 | 206 | 0.670 |
Why?
|
| Humans | 63 | 2026 | 43102 | 0.660 |
Why?
|
| Cholesterol | 2 | 2020 | 232 | 0.660 |
Why?
|
| HIV-1 | 9 | 2020 | 755 | 0.650 |
Why?
|
| Female | 49 | 2026 | 24698 | 0.610 |
Why?
|
| Male | 49 | 2026 | 23409 | 0.590 |
Why?
|
| Monocytes | 4 | 2016 | 277 | 0.580 |
Why?
|
| Antiretroviral Therapy, Highly Active | 6 | 2013 | 229 | 0.560 |
Why?
|
| Adult | 29 | 2025 | 13872 | 0.510 |
Why?
|
| Pyridones | 3 | 2025 | 50 | 0.490 |
Why?
|
| Anti-Retroviral Agents | 8 | 2024 | 160 | 0.480 |
Why?
|
| Mitochondrial Diseases | 3 | 2024 | 20 | 0.480 |
Why?
|
| Zidovudine | 7 | 2024 | 32 | 0.430 |
Why?
|
| Pregnancy | 9 | 2025 | 1772 | 0.430 |
Why?
|
| Cross-Sectional Studies | 15 | 2024 | 3156 | 0.410 |
Why?
|
| Oxidative Phosphorylation | 5 | 2024 | 60 | 0.410 |
Why?
|
| Stavudine | 5 | 2015 | 13 | 0.400 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2011 | 23 | 0.390 |
Why?
|
| Cohort Studies | 8 | 2025 | 1759 | 0.380 |
Why?
|
| Myocytes, Cardiac | 2 | 2025 | 183 | 0.380 |
Why?
|
| Uridine | 1 | 2011 | 7 | 0.360 |
Why?
|
| Middle Aged | 24 | 2025 | 12222 | 0.360 |
Why?
|
| Veterans | 4 | 2025 | 210 | 0.350 |
Why?
|
| Mitochondria, Heart | 3 | 2024 | 60 | 0.340 |
Why?
|
| Nucleosides | 1 | 2011 | 30 | 0.330 |
Why?
|
| Oxidative Stress | 5 | 2024 | 1003 | 0.330 |
Why?
|
| RNA | 2 | 2011 | 266 | 0.310 |
Why?
|
| Macrophages | 1 | 2014 | 529 | 0.310 |
Why?
|
| Subcutaneous Fat | 3 | 2019 | 19 | 0.300 |
Why?
|
| Metformin | 2 | 2020 | 75 | 0.300 |
Why?
|
| South Africa | 2 | 2025 | 38 | 0.290 |
Why?
|
| Pyruvate Kinase | 2 | 2025 | 18 | 0.290 |
Why?
|
| Infant | 7 | 2024 | 1175 | 0.280 |
Why?
|
| Myocardium | 3 | 2025 | 263 | 0.280 |
Why?
|
| HIV Seropositivity | 2 | 2012 | 196 | 0.280 |
Why?
|
| Child | 9 | 2026 | 3443 | 0.280 |
Why?
|
| Oxazines | 2 | 2024 | 32 | 0.270 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 386 | 0.270 |
Why?
|
| Young Adult | 6 | 2025 | 5080 | 0.270 |
Why?
|
| Viral Load | 6 | 2026 | 348 | 0.260 |
Why?
|
| Cell Respiration | 2 | 2017 | 35 | 0.260 |
Why?
|
| CD4 Lymphocyte Count | 8 | 2020 | 201 | 0.260 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2026 | 192 | 0.250 |
Why?
|
| Haplotypes | 2 | 2025 | 197 | 0.250 |
Why?
|
| Case-Control Studies | 6 | 2024 | 1285 | 0.250 |
Why?
|
| Infectious Disease Transmission, Vertical | 5 | 2024 | 74 | 0.240 |
Why?
|
| Adolescent | 10 | 2026 | 6081 | 0.240 |
Why?
|
| Adiponectin | 2 | 2019 | 59 | 0.240 |
Why?
|
| Disease Progression | 2 | 2025 | 667 | 0.230 |
Why?
|
| Pilot Projects | 5 | 2020 | 760 | 0.230 |
Why?
|
| Electron Transport Complex IV | 5 | 2024 | 41 | 0.230 |
Why?
|
| HIV Seronegativity | 2 | 2005 | 41 | 0.230 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2015 | 21 | 0.230 |
Why?
|
| Skin | 2 | 2015 | 187 | 0.230 |
Why?
|
| Acetylcarnitine | 1 | 2004 | 7 | 0.220 |
Why?
|
| Cognition | 2 | 2020 | 473 | 0.220 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2024 | 10 | 0.220 |
Why?
|
| Blood Coagulation Disorders | 2 | 2016 | 8 | 0.220 |
Why?
|
| Inflammation Mediators | 1 | 2026 | 140 | 0.220 |
Why?
|
| Cyclopropanes | 4 | 2024 | 46 | 0.220 |
Why?
|
| Alkynes | 4 | 2024 | 52 | 0.220 |
Why?
|
| Benzoxazines | 4 | 2024 | 47 | 0.220 |
Why?
|
| Schools, Medical | 2 | 2018 | 208 | 0.210 |
Why?
|
| Mitochondrial Proteins | 2 | 2019 | 118 | 0.210 |
Why?
|
| Lipid Metabolism | 1 | 2025 | 148 | 0.210 |
Why?
|
| Antiviral Agents | 2 | 2025 | 195 | 0.200 |
Why?
|
| Piperazines | 1 | 2024 | 120 | 0.200 |
Why?
|
| Fetus | 1 | 2004 | 101 | 0.200 |
Why?
|
| Deoxyguanosine | 2 | 2016 | 36 | 0.190 |
Why?
|
| Infant, Newborn | 4 | 2024 | 972 | 0.190 |
Why?
|
| Ritonavir | 3 | 2012 | 15 | 0.190 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2022 | 5 | 0.190 |
Why?
|
| Genome, Viral | 1 | 2023 | 119 | 0.190 |
Why?
|
| Selenoproteins | 2 | 2022 | 155 | 0.190 |
Why?
|
| Neuroblastoma | 1 | 2023 | 136 | 0.190 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 3 | 2017 | 13 | 0.190 |
Why?
|
| Longitudinal Studies | 6 | 2026 | 1063 | 0.190 |
Why?
|
| Immunity, Innate | 1 | 2023 | 171 | 0.180 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2021 | 2 | 0.180 |
Why?
|
| Endodeoxyribonucleases | 1 | 2002 | 28 | 0.180 |
Why?
|
| Fibroblast Growth Factors | 1 | 2021 | 36 | 0.180 |
Why?
|
| Interleukin-6 | 3 | 2017 | 165 | 0.170 |
Why?
|
| Energy Metabolism | 2 | 2025 | 187 | 0.170 |
Why?
|
| Child, Preschool | 5 | 2024 | 1546 | 0.170 |
Why?
|
| Ethanolamine | 1 | 2021 | 6 | 0.170 |
Why?
|
| Aged | 8 | 2025 | 8214 | 0.170 |
Why?
|
| Phospholipids | 1 | 2021 | 70 | 0.160 |
Why?
|
| Lipase | 1 | 2020 | 20 | 0.160 |
Why?
|
| Mice, Knockout | 4 | 2025 | 1035 | 0.160 |
Why?
|
| DNA Copy Number Variations | 2 | 2018 | 37 | 0.160 |
Why?
|
| Prospective Studies | 6 | 2024 | 1600 | 0.150 |
Why?
|
| Coronary Artery Disease | 2 | 2017 | 163 | 0.140 |
Why?
|
| Treatment Outcome | 3 | 2012 | 1604 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2025 | 760 | 0.130 |
Why?
|
| Nerve Fibers | 2 | 2014 | 37 | 0.130 |
Why?
|
| Oxygen Consumption | 1 | 2017 | 110 | 0.130 |
Why?
|
| Nevirapine | 3 | 2024 | 8 | 0.130 |
Why?
|
| Physical Fitness | 1 | 2017 | 90 | 0.130 |
Why?
|
| Obesity | 3 | 2024 | 1151 | 0.120 |
Why?
|
| Atrophy | 1 | 2016 | 51 | 0.120 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 41 | 0.120 |
Why?
|
| Cardiotonic Agents | 1 | 2016 | 40 | 0.120 |
Why?
|
| Brain | 2 | 2019 | 1472 | 0.120 |
Why?
|
| HIV Integrase Inhibitors | 2 | 2026 | 11 | 0.110 |
Why?
|
| Cause of Death | 1 | 2016 | 186 | 0.110 |
Why?
|
| Doxorubicin | 1 | 2016 | 97 | 0.110 |
Why?
|
| United States | 6 | 2026 | 5205 | 0.110 |
Why?
|
| Curriculum | 1 | 2018 | 318 | 0.110 |
Why?
|
| Sensory Receptor Cells | 1 | 2015 | 34 | 0.110 |
Why?
|
| Molecular Biology | 1 | 2015 | 47 | 0.110 |
Why?
|
| Reactive Oxygen Species | 3 | 2024 | 532 | 0.110 |
Why?
|
| Lipoproteins, HDL | 1 | 2014 | 48 | 0.110 |
Why?
|
| Electron Transport Complex I | 3 | 2024 | 29 | 0.110 |
Why?
|
| Lipoproteins, LDL | 1 | 2014 | 67 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 3 | 2025 | 1869 | 0.110 |
Why?
|
| Epidermis | 1 | 2014 | 23 | 0.110 |
Why?
|
| Mortality | 1 | 2016 | 175 | 0.110 |
Why?
|
| Botswana | 2 | 2024 | 5 | 0.100 |
Why?
|
| Time Factors | 4 | 2026 | 1857 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 3 | 2011 | 455 | 0.100 |
Why?
|
| Dilatation, Pathologic | 1 | 2013 | 10 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 220 | 0.100 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 77 | 0.100 |
Why?
|
| Research | 1 | 2015 | 181 | 0.100 |
Why?
|
| RNA, Viral | 3 | 2020 | 321 | 0.100 |
Why?
|
| Dideoxynucleosides | 1 | 2012 | 11 | 0.100 |
Why?
|
| Animals | 7 | 2025 | 16992 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2017 | 863 | 0.100 |
Why?
|
| Risk Factors | 5 | 2025 | 3994 | 0.090 |
Why?
|
| Drug Combinations | 1 | 2012 | 104 | 0.090 |
Why?
|
| Deoxycytidine | 1 | 2012 | 38 | 0.090 |
Why?
|
| Placenta | 2 | 2004 | 117 | 0.090 |
Why?
|
| Pyrimidinones | 2 | 2009 | 15 | 0.090 |
Why?
|
| Hippocampus | 1 | 2016 | 594 | 0.090 |
Why?
|
| Polyneuropathies | 1 | 2012 | 9 | 0.090 |
Why?
|
| Oligopeptides | 1 | 2012 | 109 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 234 | 0.090 |
Why?
|
| Mice | 4 | 2025 | 6644 | 0.090 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2012 | 38 | 0.090 |
Why?
|
| Pyridines | 1 | 2012 | 139 | 0.090 |
Why?
|
| Vascular Diseases | 1 | 2011 | 33 | 0.090 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2011 | 12 | 0.090 |
Why?
|
| Universities | 1 | 2015 | 559 | 0.090 |
Why?
|
| Pathology, Molecular | 1 | 2011 | 9 | 0.090 |
Why?
|
| NADH Dehydrogenase | 1 | 2011 | 6 | 0.090 |
Why?
|
| Viremia | 1 | 2011 | 44 | 0.090 |
Why?
|
| Exercise | 1 | 2017 | 692 | 0.090 |
Why?
|
| Bone Density | 1 | 2011 | 103 | 0.080 |
Why?
|
| Niacin | 1 | 2010 | 23 | 0.080 |
Why?
|
| Hawaii | 4 | 2020 | 2011 | 0.080 |
Why?
|
| Cytokines | 2 | 2026 | 678 | 0.080 |
Why?
|
| Cholesterol, HDL | 1 | 2010 | 99 | 0.080 |
Why?
|
| Vasodilation | 1 | 2010 | 64 | 0.080 |
Why?
|
| Extremities | 1 | 2009 | 20 | 0.080 |
Why?
|
| Vitamin D | 1 | 2011 | 196 | 0.080 |
Why?
|
| Absorptiometry, Photon | 1 | 2009 | 76 | 0.080 |
Why?
|
| F2-Isoprostanes | 1 | 2009 | 18 | 0.080 |
Why?
|
| Body Fat Distribution | 1 | 2009 | 26 | 0.070 |
Why?
|
| Lymphocyte Activation | 2 | 2020 | 249 | 0.070 |
Why?
|
| Glutathione | 1 | 2009 | 171 | 0.070 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 263 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 1067 | 0.060 |
Why?
|
| Alleles | 2 | 2018 | 352 | 0.060 |
Why?
|
| Proteins | 1 | 2008 | 382 | 0.060 |
Why?
|
| HIV | 1 | 2026 | 100 | 0.060 |
Why?
|
| HIV Wasting Syndrome | 1 | 2005 | 8 | 0.060 |
Why?
|
| Genotype | 2 | 2018 | 800 | 0.060 |
Why?
|
| Carnitine | 1 | 2004 | 7 | 0.060 |
Why?
|
| Linear Models | 1 | 2026 | 317 | 0.060 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2024 | 8 | 0.050 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2024 | 21 | 0.050 |
Why?
|
| Pyruvic Acid | 1 | 2024 | 22 | 0.050 |
Why?
|
| Erythrocebus patas | 1 | 2004 | 1 | 0.050 |
Why?
|
| Calcium-Binding Proteins | 1 | 2024 | 81 | 0.050 |
Why?
|
| Thailand | 2 | 2015 | 51 | 0.050 |
Why?
|
| Apoptosis | 1 | 2011 | 1568 | 0.050 |
Why?
|
| Respiration | 1 | 2024 | 56 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2004 | 134 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2004 | 141 | 0.050 |
Why?
|
| Microscopy, Electron | 1 | 2004 | 210 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2024 | 112 | 0.050 |
Why?
|
| Weight Gain | 1 | 2024 | 139 | 0.050 |
Why?
|
| Heart Rate | 2 | 2017 | 266 | 0.050 |
Why?
|
| Fetal Blood | 1 | 2003 | 48 | 0.050 |
Why?
|
| Glucose | 1 | 2024 | 244 | 0.050 |
Why?
|
| Comorbidity | 2 | 2017 | 737 | 0.050 |
Why?
|
| Interleukin-17 | 1 | 2022 | 53 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2016 | 986 | 0.050 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2002 | 25 | 0.050 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2002 | 29 | 0.050 |
Why?
|
| Cell Fractionation | 1 | 2002 | 29 | 0.050 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 78 | 0.050 |
Why?
|
| Indicators and Reagents | 1 | 2002 | 61 | 0.050 |
Why?
|
| Blood Glucose | 2 | 2014 | 389 | 0.050 |
Why?
|
| Magnesium | 1 | 2002 | 94 | 0.040 |
Why?
|
| Iron | 1 | 2023 | 251 | 0.040 |
Why?
|
| Aging | 2 | 2017 | 783 | 0.040 |
Why?
|
| Logistic Models | 2 | 2016 | 1009 | 0.040 |
Why?
|
| Microglia | 1 | 2023 | 208 | 0.040 |
Why?
|
| Ethanolamines | 1 | 2021 | 9 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 51 | 0.040 |
Why?
|
| Risk | 1 | 2021 | 287 | 0.040 |
Why?
|
| Phosphatidylethanolamines | 1 | 2021 | 17 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2004 | 316 | 0.040 |
Why?
|
| Glycosylphosphatidylinositols | 1 | 2021 | 19 | 0.040 |
Why?
|
| Lipogenesis | 1 | 2021 | 19 | 0.040 |
Why?
|
| Glycolysis | 1 | 2021 | 71 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2021 | 490 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2021 | 74 | 0.040 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2002 | 199 | 0.040 |
Why?
|
| CD4-CD8 Ratio | 1 | 2020 | 29 | 0.040 |
Why?
|
| Cattle | 1 | 2002 | 498 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 458 | 0.040 |
Why?
|
| Metabolomics | 1 | 2021 | 95 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2019 | 18 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 73 | 0.040 |
Why?
|
| Phenotype | 1 | 2022 | 780 | 0.040 |
Why?
|
| Brachial Artery | 2 | 2010 | 27 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 184 | 0.040 |
Why?
|
| Mutation | 1 | 2024 | 1177 | 0.040 |
Why?
|
| Organ Size | 1 | 2019 | 170 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2019 | 79 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2022 | 638 | 0.040 |
Why?
|
| Statistics as Topic | 2 | 2009 | 123 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 209 | 0.040 |
Why?
|
| Glucose Tolerance Test | 1 | 2018 | 75 | 0.030 |
Why?
|
| Homeostasis | 1 | 2019 | 192 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 719 | 0.030 |
Why?
|
| Feces | 1 | 2017 | 132 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2019 | 2544 | 0.030 |
Why?
|
| Education, Medical | 1 | 2018 | 118 | 0.030 |
Why?
|
| Japan | 1 | 2017 | 348 | 0.030 |
Why?
|
| Chromatography, Thin Layer | 1 | 2016 | 39 | 0.030 |
Why?
|
| Heterozygote | 1 | 2016 | 110 | 0.030 |
Why?
|
| DNA | 1 | 2019 | 592 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2016 | 51 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2017 | 233 | 0.030 |
Why?
|
| Leg | 1 | 2015 | 19 | 0.030 |
Why?
|
| Longevity | 1 | 2017 | 173 | 0.030 |
Why?
|
| Incidence | 1 | 2018 | 1078 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2016 | 575 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 1455 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 152 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2014 | 70 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 638 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 457 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2016 | 384 | 0.030 |
Why?
|
| Particle Size | 1 | 2014 | 272 | 0.030 |
Why?
|
| DNA Damage | 1 | 2016 | 356 | 0.030 |
Why?
|
| Oxygen | 1 | 2014 | 218 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2014 | 301 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2018 | 1413 | 0.020 |
Why?
|
| Prevalence | 1 | 2018 | 1612 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 1154 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2014 | 169 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 153 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2012 | 113 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 587 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2012 | 147 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 734 | 0.020 |
Why?
|
| Sex Factors | 1 | 2016 | 1028 | 0.020 |
Why?
|
| Age Distribution | 1 | 2012 | 249 | 0.020 |
Why?
|
| Arteries | 1 | 2011 | 81 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 440 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2011 | 63 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 2853 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2010 | 74 | 0.020 |
Why?
|
| HIV Protease Inhibitors | 1 | 2008 | 24 | 0.020 |
Why?
|
| Immunoassay | 1 | 2008 | 74 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2012 | 925 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 1081 | 0.020 |
Why?
|
| Cell Line | 1 | 2011 | 1410 | 0.020 |
Why?
|
| Diet | 1 | 2012 | 826 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2005 | 311 | 0.010 |
Why?
|
| Body Weight | 1 | 2005 | 429 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 294 | 0.010 |
Why?
|
| Base Sequence | 1 | 2003 | 983 | 0.010 |
Why?
|